ArticlePeerJ2025
MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objective: To investigate the roles of MAFF and Yes-associated protein 1 (YAP1) in regulating angiogenesis in non-small cell lung cancer (NSCLC) and to explore the mechanism through which MAFF inhibits angiogenesis by suppressing YAP1 nuclear translocation. Methods: Bioinformatics analysis was used to assess MAFF expression and its associated regulatory pathways. Clinical samples from NSCLC patients were analyzed by immunohistochemistry (IHC) to evaluate the correlation between MAFF expression and microvessel density (MVD). Cellular experiments were conducted to examine the effects of MAFF overexpression on proliferation, migration, and angiogenesis. Western blot (WB) and immunofluorescence (IF) analyses were performed to assess the expression of YAP1, vascular endothelial growth factor (VEGF), and connective tissue growth factor (CTGF). Tumor growth suppression was evaluated using nude mouse xenograft models. Results: MAFF was significantly downregulated in NSCLC tissues and correlated with advanced T stage and higher MVD. Overexpression of MAFF inhibited NSCLC cell proliferation, migration, and angiogenesis, and downregulated the expression of YAP1, VEGF, and CTGF. IF confirmed that MAFF suppressed nuclear translocation of YAP1. Conclusion: MAFF suppresses angiogenesis in NSCLC by blocking YAP1 nuclear translocation and downregulating VEGF and CTGF, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.